Amgen (AMGN.US) released mid-term data on the weight loss therapy MariTide, showing weight loss effects comparable to Novo Nordisk.

Amgen announced on Tuesday that its experimental weight loss therapy MariTide achieved significant results in Phase 2 trials.

Zhitong FinanceNov 26 08:38 ET

Altimmune to Participate at Two Upcoming Investor Conferences

GlobeNewswireNov 26 07:30 ET

White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs

WSJNov 26 05:37 ET

Trump Nominates Marty Makary For FDA Commissioner

Barron'sNov 22 22:27 ET

Executive Reshuffles: TWO, CYBR, PFG and ALT

Seeking AlphaNov 16 15:54 ET

Altimmune Presents New Data On The Effect Of Pemvidutide On Inflammatory Lipids In Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease At The Liver Meeting 2024

BenzingaNov 15 11:01 ET